drugset / Trial / NCT02567994

Tenelia Triple Combination Study

NCT02567994

Phase 3 Completed 201 enrolled Handok Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

After a screening, a 2-week, single-blind placebo run-in, 200 patients will be randomized in a 1 : 1 ratio to the addition of either once-daily Teneligliptin 20mg or sitagliptin 100mg to ongoing stable doses of glimepiride in combination with metformin for 24 weeks.

Timeline

Start
2015-04
Primary completion
2017-10
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Teneligliptin Small molecule 20 mg